How research peptides are made: synthesis, purification and testing

What is being made? Start with the material specification

If you are comparing research listings, understanding manufacture helps you ask useful questions about the material offered. It does not tell you which supplier is best from a slogan about its process. This guide connects the broad manufacturing concepts with the documents a procurement decision should retain. It does not establish the manufacturing site, route or release status of any partner’s inventory.

IUPAC defines peptides as compounds formed from two or more amino carboxylic acids joined through amide bonds. In ordinary peptide discussion, these units are usually amino acids. The sequence identifies their order. A description such as “synthetic peptide” therefore needs more detail than the number of units: the intended material must be specified. [1][2]

Chemical synthesis links amino acids in a chosen sequence. Selective protection temporarily limits which reactive groups participate, helping avoid unintended connections. Bachem’s explanation describes this as a matter of controlling sequence direction and the reactive groups of the building blocks. Naming that principle is different from providing the conditions needed to run a reaction. [2]

For a purchase record, write down the complete item identity, stated formulation, package amount and physical form. Ask the supplier for the specification that its batch is meant to meet. Keep a branded name or convenient alias attached to that specification; do not let it stand in for missing identity information.

Solid-phase peptide synthesis: a chain attached to a support

In solid-phase peptide synthesis, usually abbreviated SPPS, the growing peptide remains attached to an insoluble support, commonly a resin. Protected amino acids are added to build the chain. Keeping the intended chain on the support allows liquid reagents and many soluble by-products to be removed while assembly continues. After assembly, the peptide is released from the support. [3]

The solid support is a tool for managing the chemistry; it is not the final material being purchased. The conceptual advantage is repeated separation of the supported chain from the surrounding liquid. This makes a repeated assembly process practical, but the manufacturing description does not report the final batch’s analytical results. Those results still need to be read from its own documentation. [3]

Solution-phase synthesis: assembly in solution

Solution-phase peptide synthesis performs the assembly without an insoluble resin carrying the growing chain. The chemistry and isolation strategy require product-specific planning. Bachem’s methods overview treats liquid-phase and solid-phase approaches as distinct tools and also describes fragment-joining methods. The existence of several approaches is a reason to ask which route was actually used, rather than assume every listing has the same manufacturing history. [4]

Some modern liquid-phase approaches use soluble tags to assist separation during manufacture. The tag serves a handling role while the material is being built in solution. Bachem’s 2025 explanation describes such approaches and their trade-offs. A soluble tag is not the same as an insoluble solid-phase resin, and that particular approach should not be assumed from the broad words “solution synthesis.” [5]

For procurement, a disclosed route is background information. It can help frame questions about process control and the specified material. It does not supply a numerical purity result, establish delivery performance or authenticate a seller’s current lot. If the seller does not disclose its route, record that as an unknown instead of attributing a method from a general article.

Why purification follows peptide assembly

Assembly can leave a mixture. Bachem’s purification guide identifies incomplete or altered peptide products, residual reagents and other process by-products among the possible constituents of crude material. A completed chain-building process is therefore not the same claim as a purified target preparation. [6]

Preparative chromatography separates material for collection. Reversed-phase high-performance liquid chromatography, or RP-HPLC, is a common peptide purification approach: different components interact differently with the chromatographic system, allowing useful fractions to be separated. Analytical checks guide which collected fractions meet the specified purity. Purification can require further work if closely related material is not sufficiently resolved. [6]

Isolation and drying address the physical material after purification. Lyophilization, often called freeze-drying, can turn a purified peptide solution into a powder. A powder’s appearance is not an analytical identity or content result. The relevant evidence is the testing and specification linked to that material, rather than whether a photograph looks like a typical vial. [6]

Identity, purity and content answer different questions

The useful question is not “What is the purity score?” in isolation. Separate the claimed identity, the method-specific impurity result and the amount being measured. Read the following three concepts as different parts of a material description. Their relationship is explained in the sources below; no example here is a result for a listed partner.

Identity testing asks whether observations are consistent with the intended material. In Thermo Fisher’s application study, mass spectrometry supported peptide peak assignment and mass-based compound confirmation alongside chromatography. UV peaks alone did not provide those assignments. Our procurement interpretation is to request the expected identity and the actual supporting result, rather than treat an unlabeled chromatogram as a complete identity record. [9]

Chromatographic purity describes a result within a separation and detection method. Bachem’s FAQ explains its HPLC-UV purity as the requested peptide’s share relative to detected absorbing material under the stated method. That ratio is not automatically a mass measurement of every constituent in a vial. Ask which method produced the percentage and which material the result describes. [8]

Peptide content addresses a different denominator. A dried sample can include water, counterions and other non-peptidic material. Bachem distinguishes net peptide content from chromatographic purity; its definition of net peptide content includes peptidic impurities as well as the desired peptide. Thus “net peptide content,” target-peptide quantity and main-peak purity should not be silently treated as three interchangeable labels. [7]

NIST’s record for research using angiotensin I describes several approaches to assigning peptide purity mass fraction, including mass balance, impurity-corrected amino acid analysis and quantitative nuclear magnetic resonance. The point for a reader is the defined measurand and measurement basis. A method name or percentage without that basis can leave the interpretation unresolved. [10]

An interlaboratory study using oxytocin compared HPLC assay, quantitative NMR and amino acid analysis. In that specific study, HPLC assay using the same bulk peptide material as the standard had the lowest between-laboratory variability; the reported calculation did not include the standard’s mass-balance purity uncertainty. That result is specific to its study design. It does not identify one universal best assay for all peptides or certify a partner’s method. [11]

Connect the document to the batch being offered

Bachem’s analytical-document description includes lot number, product designation, sequence and tests performed. Its FAQ also explains that data sheets concern the actual batch. These details make the document useful as evidence about specified material. A generic testing statement on a supplier homepage does not supply the same connection. [8]

When reviewing a supplier report, record the issuing laboratory, sample identifier, report number, date, lot identifier and reported methods. Compare those fields with the offered product and package record. If a field is missing, request it. If identifiers disagree, retain the discrepancy and seek an explanation before relying on the report for that procurement decision.

Some laboratories provide a direct authenticity check. Janoshik’s official verification page, for example, asks for a task number and unique key. Use the issuing laboratory’s own route when available and compare its record with the supplied document. Our documentation interpretation is that authenticity and sample-to-lot matching remain separate checks: authenticating a report does not show which lot a seller will ship. [13]

Analytical scope also matters. Janoshik lists peptide analysis separately from heavy-metal screening, contamination screening, endotoxin analysis and microbiological testing. Do not assume that an identity or purity report contains those additional measurements. Read the actual tests and results listed on the report and confirm the required scope with the laboratory for the research purpose. [12]

Use the peptide COA guide and printable checklist

Read more about HPLC, LC-MS, purity and measured content

Use exact packages to keep the purchase comparison defined

BPC-157 and GHK-Cu below are catalogue examples for practicing package and document checks. They are different identities, not substitutes for one another. These links make no clinical or biological recommendation, and this article does not assert how either supplier batch was manufactured. Use the current comparison to inspect the named package, available offers and the recorded source dates.

Inspect current BPC-157 10mg Vial package offers

Inspect current GHK-Cu 50mg Vial package offers

Our catalogue method keeps identity, size, form, market and currency together. A capsule, spray, blend and lyophilized vial are not automatically equivalent. The displayed price is a recorded item price; final delivery, tax and accepted checkout conditions require their own checks. A referral parameter does not by itself prove a price reduction, and commission does not determine price order. [14]

Here is a documentation exercise rather than a supplier quote: suppose two listings both say “10mg Vial,” but one provides only a general purity image while the other provides an identifiable batch report. Record the evidence available from each. Do not invent a measured quantity for either or convert a missing report into a numerical quality ranking. The next step is to request the information your project requires.

Keep the comparison and analytical decision together in your procurement notes: the selected package, the supplier offer URL, source observation date, requested lot, report identifiers, stated tests, unresolved questions and the final quote. A later price update should not overwrite the analytical evidence you retained. Likewise, an older laboratory document should remain attached to its original sample rather than become a new test of the current listing.

What the explainer and comparison can establish

This article explains general manufacturing and measurement concepts. PeptideTech is a comparison and vendor directory. The manufacturer sources are cited for their explanations, not as evidence that they supply any partner in our directory. We have not reconstructed a partner’s supply chain from an article about SPPS.

The comparison method describes how listing information is recorded. A captured price or linked COA does not independently verify purity, sterility, clinical suitability, effectiveness, delivery or supplier reliability. Supplier statements are attributed to the supplier unless a specific independent verification record establishes more. The practical outcome is an explicit evidence record, including what remains unknown. [14]

After those checks, use the product page to inspect the selected offer and continue to the supplier for its current terms and final cart. Retain the actual accepted quote and documentation for your institutional purchasing process. The goal is a defined, reviewable purchase record; manufacturing terminology and a low price should never hide a missing answer.

Review the current price and identity comparison method

Check current supplier evidence sources